
Moleculin Biotech Inc’s (NASDAQ:MBRX) New Drug For Glioblastoma Undergoes Clinical Trials At MD Anderson Cancer Center
Moleculin Biotech Inc (NASDAQ:MBRX) recently announced that it will provide the needed support to enable the start of clinical studies for its new drug application













